Who is sponsoring REDUCE-1?

REDUCE-1 is sponsored by Idorsia Pharmaceuticals Ltd..

What condition does REDUCE-1 study?

REDUCE-1 studies Essential Hypertension.

What drugs are being tested in REDUCE-1?

Interventions: ACT-280778, Placebo, Amlodipine.

What is the status of REDUCE-1?

REDUCE-1 is currently COMPLETED.

Last reviewed 2018-09-26 · How we verify

A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension (REDUCE-1)

NCT01264692 Phase 2 COMPLETED

The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.

Details

Lead sponsor	Idorsia Pharmaceuticals Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	196
Start date	2011-02
Completion	2012-02

Conditions

Essential Hypertension

Interventions

ACT-280778
Placebo
Amlodipine

Primary outcomes

Change in mean(c) trough(d) SiDBP — Baseline to day 28
Change from baseline(b) to Day 28 (± 2 days) of Period 2 (Visit 7)in mean(c) trough(d) SiDBP.

Countries

Israel, Serbia